AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01225380
Drug: Copegus®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ribavirin 200 mg tablet (weight based: 1000 mg/day \<75 kg; 1200 mg/day \>/= 75 kg) divided twice daily (BID), up to 48 weeks
Trial: NCT01429506
Drug: Intensive medical management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exenatide 10 mcg BD, Metformin 2-3 gm/day, 800 Kcal diet
Trial: NCT04358432
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered by subcutaneous injection
Trial: NCT01042938
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients take 2.0 grams placebo (four 500mg capsules) three times daily by mouth for prescribed course of radiation treatment (\~4-7 weeks)
Trial: NCT03325790
Drug: 200mg SPI-1005 BID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active: low dose
Trial: NCT03231124
Drug: LEO 32731
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: LEO 32731 is being developed by LEO Pharma.
Trial: NCT03231124
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo contains the same excipients in the same concentration, only lacking LEO 32731
Trial: NCT04387539
Drug: SOF/SMV/DCV/RBV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SOF was given orally at a dose of 400 mg/day DCV was given orally at a dose of 60 mg/day SMV was given orally at a dose of 150 mg/day. RBV was given in a total daily oral dose of 600 mg/day up to 1,200 mg/day according to the participant's weight and tolerability.
Trial: NCT04144712
Drug: Caffeine Citrate
RxNorm normalized name: Caffeine Citrate
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: study rate of occurrence of Apnea of Prematurity between the 2 groups
Trial: NCT03285607
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: -Standard of care
Trial: NCT03285607
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: -Standard of care
Trial: NCT01251770
Drug: 0.45% NaCl/dextrose 5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects in this arm will receive 0.45% NaCl/dextrose 5% intravenous (IV) maintenance fluids.Total daily fluid infusion equal to: 80 ml/kg/day for those weighing up to 10 kg, and 1500 ml/m\^2 body surface.
Trial: NCT01251770
Drug: 0.3% NaCl/dextrose 5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: 0.3% NaCl/dextrose 5% IV maintenance fluids. Total daily fluid infusion equal to: 80 ml/kg/day for those weighing up to 10 kg, and 1500 ml/m\^2 surface.
Trial: NCT01355874
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo ointment BID for 14 days during double blind.
Trial: NCT02412735
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline control solution
Trial: NCT01287325
Drug: DNK333 100 mg twice daily
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01287325
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00633269
Drug: AZD2281
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100mg Oral Dose
Trial: NCT03405090
Drug: Fentanyl Citrate
RxNorm normalized name: Fentanyl Citrate
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 100 mcg fentanyl citrate will be inhaled via nebulizer
Trial: NCT03176264
Drug: PDR001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg every 4 weeks
Trial: NCT03176264
Drug: mFOLFOX6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of chemotherapy administered every 2 weeks: oxaliplatin (85mg/m2), 5-Fluorouracil (2400mg/m2) and folinic acid (=leucovorin, 400mg/m2)
Trial: NCT01508949
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily dosing of 0.6 mg for 8 weeks, injected subcutaneously
Trial: NCT00230750
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline placebo.
Trial: NCT00941278
Drug: PH-10 (0.001% Rose Bengal)
RxNorm normalized name: prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PH-10 will be applied daily for 28 days to skin areas affected by mild to moderate psoriasis.
Trial: NCT02838628
Drug: 50 mg of KX2-391 Ointment 1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose: 50 mg; Route of administration: Topical
Trial: NCT01008553
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: One-day adhesive transdermal patch containing fentanyl 12.5 to 50 mcg/hr applied to chest, abdomen, upper arm and thigh and replaced every day.
Trial: NCT01008553
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo patch indistinguishable from one-day adhesive transdermal patch containing fentanyl 12.5 to 50 mcg/hr applied to chest, abdomen, upper arm and thigh and replaced every day.
Trial: NCT02547571
Drug: High volume PEG split-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colyte® or PegLyte® will be provided to the subject who will be asked to drink 2L of the preparation starting at 7:00 PM the day before the procedure at a rate of 240 mL every 10 minutes until completed. The second dose of 2L of preparation will be taken the morning of the colonoscopy starting 4-5 hours prior to the planned procedural time at a rate of 240 mL every 10 minutes until completed.
Trial: NCT02547571
Drug: Low volume PEG split-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bi-PegLyte® will be provided to the subject who will be asked to ingest 3 tabs of Bisacodyl 5 mg (total 15 mg) at 2:00 PM the day before the procedure. After the first bowel movement, or if there is no bowel movement within 6 hours of taking the Bisacodyl tablets, the subject will be asked to drink 1L of the solution at a rate of 240 mL every 10 minutes until the solution is completed. The second dose of 1L of preparation will be taken the morning of the colonoscopy starting 4-5 hours prior to the procedure at a rate of 240 mL every 10 minutes. Use of antacids will not be permitted within one hour of taking bisacodyl.
Trial: NCT02547571
Drug: High volume PEG non split, day before
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colyte® or PegLyte® will be provided to the subject who will be asked to drink 4L of preparation starting at 6:00 PM the day before the procedure, at a rate of 240 mL every 10 minutes until completed.
Trial: NCT02847429
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02547571
Drug: Low volume PEG non split, same day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bi-PegLyte® will be provided to the subject, who will be asked to ingest 3 tabs of Bisacodyl 5 mg (total 15 mg) at 2:00 PM the day before the procedure and will drink 2L of preparation the morning of the colonoscopy starting 4 hours prior to the procedure at a rate of 240 mL every 10 minutes, until completed. Use of antacids will not be permitted within one hour of taking Bisacodyl.
Trial: NCT00224523
Drug: GW685698X
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00241488
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01720576
Drug: REGN1033 (SAR391786)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01720576
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03257995
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule containing no active ingredients delivered via Concept1 device
Trial: NCT03422575
Drug: Etoricoxib 120Mg Film-coated Tablet
RxNorm normalized name: etoricoxib 120 MG
DrugBank: Etoricoxib (DB01628)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One tablet of the Test drug was given orally (swallowed with 200 mL of water, without chewing), after an overnight fast, and after fasting (pre-dose) blood-sampling.
Trial: NCT03422575
Drug: Arcoxia® 120 mg Film-coated tablet (Frosst Iberica S.A., Spain for Merck Sharp & Dohme (Australia) Pty Limited, Australia, registered by PT. Schering-Plough Indonesia Tbk)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One tablet of the Reference drug was given orally (swallowed with 200 mL of water, without chewing), after an overnight fast, and after fasting (pre-dose) blood-sampling.
Trial: NCT01022541
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine 1700mg/m2/day in two divided doses to be administered orally for 14 days followed by 7 days rest. For 4 courses initially.~(For patients aged 75+ 1300mg/m2/day in two divided doses or 650mg/m2 twice daily)~Courses as per detailed description above.
Trial: NCT04320615
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive 1 dose of IV placebo matched to TCZ. Up to 1 additional dose may be given if clinical symptoms worsen or show no improvement.
Trial: NCT03559062
Drug: TEZ/IVA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants weighing \<40 kg received TEZ 50 mg/IVA 75 mg FDC tablet and those weighing ≥40 kg received TEZ 100 mg/IVA 150 mg FDC tablet.
Trial: NCT03559062
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matched to TEZ/IVA FDC
Trial: NCT02349152
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects in the experimental group will receive remifentanil infusion 0.1-0.4ug/kg/minute before induction of anesthesia and continued until skin closure. During cardiopulmonary bypass, remifentanil infusion will be increased to 0.5-1 ug/kg/min as hemodynamically tolerated.
Trial: NCT02349152
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Subjects in the control group will initially receive intermittent boluses of Fentanyl in the range of 50-250 ug. Additional fentanyl can be given titrated to hemodynamic parameters throughout surgery.
Trial: NCT03272503
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Identical matching placebo lactose tablets
Trial: NCT01218347
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 20 mg once daily for 21 days
Trial: NCT03903718
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is salt-water solution containing no active ingredients and administered as a single IV infusion on Day 2.
Trial: NCT01594827
Drug: Placebo (Sterile Water)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: On Days 1-28, subjects will receive 5cc of a nebulized Placebo (Sterile water) twice a day. This is a taste (quinine 0.1mg/mL) matched nebulized placebo (sterile water). Patients will use a Pari Sprint nebulizer and Pari Vios compressor as the delivery system.
Trial: NCT01594827
Drug: Doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: If sulfa intolerant or TMP/SMX Resistant, use instead oral doxycycline~1. \>45 kg: 100 mg by mouth twice a day~2. 35-45 kg : 75 mg by mouth twice a day iii. 25-34.9 kg: 50 mg by mouth twice a day
Trial: NCT02677870
Drug: saproterin dihydrochloride
RxNorm normalized name: Sapropterin Dihydrochloride
DrugBank: Sapropterin (DB00360)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: The drug will be given as described in the arm/group descriptions.
Trial: NCT01100606
Drug: EUR-1008 (APT-1008)
RxNorm normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EUR-1008 (APT-1008) (Zenpep® \[pancrelipase\] delayed release capsule) from open capsule, mixed with a small amount of apple juice, will be given orally daily using a syringe nurser at dose increments of 3,000 lipase units, for 10 days in either first treatment period or second treatment period. Total dose will not exceed 10,000 lipase units per kilogram (kg) of body weight per day.
Trial: NCT01100606
Drug: EUR-1008 (APT-1008)
RxNorm normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EUR-1008 (APT-1008) (Zenpep® \[pancrelipase\] delayed release capsule) from open capsule, mixed with a small amount of apple sauce, will be given orally daily using a spoon at dose increments of 3,000 lipase units, for 10 days in either first treatment period or second treatment period. Total dose will not exceed 10,000 lipase units per kg of body weight per day.
Trial: NCT02658877
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline with a volume of injection frequency indicated based on the patient's serum IgE and body weight, delivered subcutaneously and supplied by Novartis Pharma.
Trial: NCT03638076
Drug: RTV
RxNorm normalized name: Accu-Chek SmartView Test Strips
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subject in group A will receive Ritonavir tablet 100mg twice daily.Subject in group B will receive Ritonavir tablet 100mg three times daily.
Trial: NCT00346905
Drug: Enteryx
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03120468
Drug: Topiramate and N-Acetyl Cysteine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topiramate up to 200 mg/day and N-Acetyl Cysteine 600 mg twice a day for 12 weeks
Trial: NCT04366713
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered orally twice daily at 750 mg/m\^2 for 14 days of each 21 day treatment cycle
Trial: NCT02406209
Drug: NS2
RxNorm normalized name: NS2B-3 proteinase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NS2 ophthalmic drops (0.5%)
Trial: NCT02406209
Drug: Prednisolone acetate ophthalmic suspension (1%)
RxNorm normalized name: prednisolone acetate Ophthalmic Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03251560
Drug: Fuke Qianjin capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fuke Qianjin capsule 0.8g pills by mouth, three times daily
Trial: NCT03251560
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral capsule 0.8g pill by mouth, three times daily
Trial: NCT03331627
Drug: STR001-IT and STR001-ER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: STR001-IT intrataympanic injection and STR001-ER tablet
Trial: NCT00335140
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 25 mg PO/IV every 6 hrs. x 12 doses, Weeks 1, 3, 5, 7, 9 For patients with meningeal involvement additionally 10 mg PO every 12 hrs. x 8 doses, Weeks 2, 4, 6, 8, 10
Trial: NCT00335140
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3.5 g/m2In 500 cc D5W + 25 mEq NaHCO3 IV over 2 hours, Weeks 1, 3, 5, 7, 9~For patients with meningeal involvement additionally:~12 mg Intrathecally, in preservative-free sterile .9NS Weeks 2, 4, 6, 8, 10 Via Ommaya or lumbar puncture
Trial: NCT03901716
Drug: Sufentanil
RxNorm normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients in Group S received sufentanil 0.1 mcg/kg.
Trial: NCT03901716
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients in Group F received fentanyl 1 mcg/kg.
Trial: NCT03901716
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients in Group R received remifentanil target-controlled infusion with effect-site target concentration of 1ng/ml.
Trial: NCT03738475
Drug: TIMP-GLIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg/kg up to a maximum of 650 mg administered intravenously on days 1 and 8.
Trial: NCT03738475
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered intravenously on days 1 and 8.
Trial: NCT00852137
Drug: PEP005 (ingenol mebutate) Gel, 0.05%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEP005 (ingenol mebutate) Gel 0.05% once daily for 2 consecutive days
Trial: NCT01384162
Drug: sNN0029
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICV infusion
Trial: NCT02470780
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching Rifaximin treatment.
Trial: NCT01023958
Drug: BI 6727, IV infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: phase II
Trial: NCT04334512
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Treatment with azithromycin
Trial: NCT00742326
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one capsule daily
Trial: NCT00852137
Drug: Vehicle Gel
RxNorm normalized name: vehicle gel base no.61
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle Gel once daily for 2 consecutive days
Trial: NCT00922688
Drug: Dipeptide Alanyl-Glutamine
RxNorm normalized name: Alanyl-glutamine dipeptide
DrugBank: Alanyl glutamine (DB11876)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous supplementation of the dipeptide alanyl-glutamine is started 24 hours prior to surgery (dosage glutamine: 0,5 g/kg/day, and continued 24 hours postoperatively.
Trial: NCT00922688
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous and enteral supplementation of placebo is started 24 hours prior to surgery and continued 24 hours postoperatively.
Trial: NCT00922688
Drug: Dipeptide Alanyl-Glutamine
RxNorm normalized name: Alanyl-glutamine dipeptide
DrugBank: Alanyl glutamine (DB11876)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteral supplementation of the dipeptide alanyl-glutamine is started 24 hours prior to surgery (dosage glutamine: 0,5 g/kg/day, and continued 24 hours postoperatively.
Trial: NCT01244139
Drug: BIIB033
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion of 0.3, 1, 3, 10, 30, 60 or 100 mg/kg
Trial: NCT01244139
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion dummy drug
Trial: NCT02268994
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo
Trial: NCT00108251
Drug: Eplerenone
RxNorm normalized name: Eplerenone
DrugBank: Eplerenone (DB00700)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: aldosterone receptor blocker
Trial: NCT00108251
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo
Trial: NCT02635893
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo pill will be administered instead of medication by mouth
Trial: NCT01342185
Drug: Diammonium glycyrrhizinate Capsules
RxNorm normalized name: glycyrrhizinate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: Diammonium glycyrrhizinate Capsules Patients in this group will receive oral Diammonium glycyrrhizinate Capsules 150mg, three times a day for 12 weeks.
Trial: NCT02459457
Drug: Paclitaxel and Fluorouracil
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: patients get Paclitaxel and Fluorouracil according to protocol
Trial: NCT00477490
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebo placed under the participant's tongue, without water, once daily approximately 1 hour before bedtime.
Trial: NCT00743587
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral, a double-dummy approach will be used to maintain the blind between active tablet and capsule doses
Trial: NCT02498782
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04230122
Drug: LY3478006 - IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered IV
Trial: NCT04230122
Drug: LY3478006 - SC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT04230122
Drug: Placebo - IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered IV
Trial: NCT00743587
Drug: Naproxen
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral, 1 x 500mg enteric-coated
Trial: NCT00902746
Drug: NPC-01
RxNorm normalized name: ALCOHOL 377.5 mL in 500 mL TOPICAL GEL [ANIOSGEL 85 NPC]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This study consist of the following steps.~Step 1(Norethisterone 0.6mg, Ethinyl Estradiol 0.035mg):From first study medication to 3th menstrual cycles.~Step 2(Norethisterone 1mg, Ethinyl Estradiol 0.035mg):~After interim analysis of the results of step 1, in the case of the efficacy results meet prespecified criterion, same dose level will be continued to 13th menstrual cycles including step 1. If the results do not meet prespecified criterion, the dose will be increased to Norethisterone 1mg, Ethinyl Estradiol 0.035mg and be continued newly until 13th menstrual cycle from this point.
Trial: NCT03598153
Drug: Shujinjianyao Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: According to the usage and dosage of the instructions, patients should use the medicine dialectically and rationally for 4 weeks.
Trial: NCT01546532
Drug: RLX030
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RLX030 as intravenous infusion for 24 hours.
Trial: NCT01546532
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of Placebo over 24 hours